Our Studies Show the Potential for Disease Inhibition Without Toxicity

SanRx's founder, Dr. Phillip Moheno, began studying active pterins in the 1970's while at UCLA. Pterin occurs naturally in humans and in animals and is an integral and necessary part of their biological function. Pterin is present in human cells, amniotic fluid, urine and other body fluids. Pterin gives butterfly wings their color and is a component of folic acid, a well known B vitamin.

Dr. Moheno's studies led to the successful testing of pterin plus calcium in mice for inhibiting mouse mammary gland cancers. It was observed that pterin plus calcium favorably altered levels of certain immune system substances connected to human-like tumor growth in mice. No toxicity was observed in these mice at three times the therapeutic dose. Lowered IDO (indoleamine 2,3-dioxygenase) levels were also observed. High levels of IDO have been linked to tumor growth.

Timeline of Discovery »

A Promising New Drug – DCP – Emerges

Subsequently, the very promising drug, DCP (dipterinyl calcium pentahydrate), was developed by Dr. Moheno and his team with the expectation that it would even improve on the results obtained with pterin plus calcium. In mouse studies (mice with human-like breast cancer tumors) with DCP performed by a reputable third-party laboratory, the results were dramatic. More favorable levels of IDO and cytokines connected with enhancing cancer immunity were observed. No toxicity was detected at three times the therapeutic dose of DCP. The study involved 12 mice. The mice administered DCP experienced highly significant (p < ..0001) halting of tumor growth with DCP. Every one of the control mice receiving no DCP experienced significant tumor growth.

We believe that these mouse studies are unusually predictive of effectiveness in humans. Historically, mouse studies, where even a small statistically significant positive response was found, have led to useful and profitable drugs for human cancer therapies. In this case, there was a highly significant response, with the DCP-treated mice experiencing a strong halting of tumor growth. In addition, the immune mechanism tied to IDO, as it relates to tumor growth, appeared to be the same in humans and mice.

Decreasing IDO Enhances the Immune System's Effectiveness Against Disease

SanRx's data indicate that the likely mechanism of action of DCP is to inhibit action of the key immune system enzyme, IDO, which has been linked to immune response of T cells, B cells, Natural Killer cells and dendritic cells. Increased IDO levels allow cancer cells to escape destruction by the immune system. In a healthy immune system with normal levels of IDO, cancer cells are identified and destroyed by an immune system response. By therapeutically decreasing IDO levels in an abnormal immune system that has elevated IDO levels with pterin plus calcium or DCP, the immune system's ability to destroy cancer cells is restored and enhanced.

Increased IDO levels have been associated with the incidence of breast cancer, squamous cell carcinoma, lung cancer, uterine cancer, colorectal cancer, and melanoma.


Below is a list of the patents SanRx has been awarded to date. Additional global and new product patents are in progress.

  • Moheno, P. 2011. Novel pterin antineoplastic agents. Japanese Patent Registration
    No. 4780834.

  • Moheno P., Pfleiderer, W. 2010. Dipterinyl calcium pentahydrate (DCP) and therapeutic methods based thereon. United States Patent 7,662,820.

  • Moheno, P. 2002. Pterin antineoplastic agents. United States Patent 6,358,953.

  • Moheno, P. 1996. Anti-neoplastic compositions and methods for application thereof. United States Patent 5,534,514.


The following publications by SanRx have appeared in medical journals.